Bon Natural Life Limited (BON) has seen a push of 53.78% in the aftermarket because the company announced the fiscal year 2021 results. However, the last trading session closed at $3.3 with an increase of 1.66%.
The fiscal Year 2021 Results – Revealed by BON!
On 2nd February 2022, BON announced the fiscal year 2021 results. The company reported net revenue of about $25.5 million with a 39.9% increase. Moreover, the gross profit came out to be $7.1 million. Not only this but the general and administrative expenses stated were $1.3 million with a 3.2% decrease. Furthermore, the adjusted EBITDA increased by 46.5% to reach $6.1 million. Last but not the least, net income totaled $4.6 million.
Now what?
Bon Natural Life Limited (BON) is thrilled with the business’s strong demand trends and double-digit revenue growth and record revenue. Moreover, these figures are clear evidence about the refined product offering, dedication to development, and status as a key partner to the clients. Due to the prolonged worldwide pandemic, changes in trade relations, and macroeconomic policies, BON has confronted worldwide supply-chain issues.
Furthermore, the company is optimistic about the group’s ability to manage these circumstances and completely offset challenges over time as they adjust the product mix toward higher-end and better profit commodities in order to boost the pricing power, enhance net profit, enhance quality, and maintain solid cost discipline.
Initial Purchase Order – What is it?
BON announced on 12th January 2022 that Chongqing Fudoudou Technology Co., Limited has granted them an initial purchase order for the FeatherPure Women’s Personal Care Gel. The company is very happy to begin working with FDD. This is a once-in-a-lifetime chance for BON to expand its reach into FDD’s enormous retail customer network.
As women’s health awareness grows, BON expects women’s health expenditure to grow geometrically. And FeatherPure to take the lead in the market. Simultaneously, BON is in talks with FDD about co-developing new healthcare items in response to overwhelming market demand. They anticipate that their relationship with FDD will provide an additional source of revenue growth, with a revenue increase of US$10 million predicted in three years, as well as more attractive value to the shareholders.
